American College of Rheumatology (ACR)

Early and Sustained Reduction in Severity of Skin Disease With Anifrolumab Treatment in Patients With Active SLE Measured by the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI): Pooled Data From 2 Phase 3 Studies

Flare Reduction and Oral Corticosteroid Taper in Patients With Active SLE Treated With Anifrolumab in 2 Phase 3 Trials

Comprehensive Efficacy of Anifrolumab Across Organ Domains in Patients With Active SLE: Pooled Data From 2 Phase 3 Trials

What Does it Mean to be a BICLA (BILAG-Based Composite Lupus Assessment) Responder? Post Hoc Analysis of the Phase 3 TULIP-1 and TULIP-2 Trials

Lupus Disease Activity After Cessation of Anifrolumab Treatment During the Phase 2b MUSE Trial Follow-up Period

Herpes Zoster Events With Anifrolumab in Patients With Active SLE: An Integrated Analysis of Phase 2 and Phase 3 Trials